The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 06, 2024

Filed:

Aug. 26, 2016
Applicants:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Wayne State University, Detroit, MI (US);

Inventors:

Carl H. June, Merion Station, PA (US);

Michael Milone, Cherry Hill, NJ (US);

Yangbing Zhao, Lumberton, NJ (US);

Lawrence G. Lum, Charlottesville, VA (US);

Archana Thakur, Charlottesville, VA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2006.01); C07K 16/32 (2006.01); C12N 15/09 (2006.01); A61K 35/17 (2015.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61K 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); A61K 35/00 (2013.01); A61K 39/0011 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/43 (2013.01); C07K 2319/50 (2013.01);
Abstract

The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.


Find Patent Forward Citations

Loading…